Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL16268586 | 0.98 | MEN1 (0.61) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL10054980 | 0.89 | SIGMAR1 (0.50) | MEN1KMT2ATDP1CHRM2SIGMAR1 | |
| SCHEMBL1443953 | 0.88 | MAOA (0.64) | MEN1KMT2ATDP1MAOACHRM2 | |
| Hydrochloric Acid SCHEMBL21493579 | 0.86 | MAOA (0.62) | MEN1KMT2ATDP1MAOACHRM2 | |
| Methacrylic Acid SCHEMBL29650344 | 0.85 | HDAC1 (0.48) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL16151778 | 0.85 | CHRM2 (0.63) | MEN1KMT2ATDP1MAOACHRM2 | |
| Hydrochloric Acid SCHEMBL29778342 | 0.83 | CHRM2 (0.61) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL18615003 | 0.83 | HDAC1 (0.46) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL4502698 | 0.83 | MEN1 (0.70) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL8944637 | 0.82 | SIGMAR1 (0.68) | MEN1KMT2ATDP1MAOACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024154978-A1 | AMPHIPATHIC POLYAMIDE-BASED REVERSE OSMOSIS SEPARATION MEMBRANE WITH IMPROVED FOULING RESISTANCE AND WEAR RESISTANCE AND MANUFACTURING METHOD THEREFOR | 도레이첨단소재 주식회사 | 2024-07-25 | — | — | WO | claimed |
| CN-115943072-A | Gas activated cyanoacrylates for 3D printing | 汉高股份有限及两合公司 | 2023-04-07 | — | — | CN | claimed |
| US-20220002576-A1 | GAS-ACTIVATED CYANOACRYLATES FOR 3-D PRINTING | HENKEL AG & CO KGAA (DE) | 2022-01-06 | — | — | US | claimed |
| EP-3708370-A1 | 3D-PRINTING METHOD USING GAS-ACTIVATED CYANOACRYLATES | Henkel AG & Co. KGaA (DE) | 2020-09-16 | — | — | EP | claimed |
| EP-3144072-A1 | DISPENSER, KIT AND METHOD FOR APPLYING AN ACTIVATOR FOR A CURABLE CYANOACRYLATE-BASED COMPONENT | Henkel AG & Co. KGaA (DE) | 2017-03-22 | — | — | EP | claimed |
| US-7618912-B2 | Preparation of supported catalyst systems | BASELL POLYOLEFINE GMBH (DE) | 2009-11-17 | — | — | US | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2007006585-A2 | SYNTHESIS OF A POROUS AND/OR STRATIFIED STRUCTURE MANGANESE OXIDE | ELSPER RUEDIGER (DE) | 2007-01-18 | — | — | WO | claimed |
| US-20060166813-A1 | Preparation of supported catalyst systems | BASELL POLYOLEFINE GMBH (DE) | 2006-07-27 | — | — | US | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | claimed |
| US-6352810-B1 | Toner coagulant processes | XEROX CORPORATION | 2002-03-05 | — | — | US | claimed |
| EP-0559835-B1 | CONSUMER POLYOLEFIN PRIMER | LOCTITE CORP (US) | 1998-06-17 | — | — | EP | claimed |
| US-5314562-A | Bonding a plastic substrate with an alpha-cyanoacrylate adhesive in which a primer comprising an ethylenediamine is used | LOCTITE CORPORATION (US) | 1994-05-24 | — | — | US | claimed |
| EP-0559835-A1 | CONSUMER POLYOLEFIN PRIMER | LOCTITE CORPORATION (US) | 1993-09-15 | — | — | EP | claimed |
| WO-1992009669-A1 | CONSUMER POLYOLEFIN PRIMER | LOCTITE CORPORATION (US) | 1992-06-11 | — | — | WO | claimed |
| EP-3474901-B1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B V (NL) | 2025-08-06 | — | — | EP | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| EP-0178947-A2 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
| US-4510082-A | NONHABIT-FORMING ANALGESICS | ELI LILLY AND COMPANY (US) | 1985-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | MEN1 1886/4885KMT2A 2113/4885TDP1 716/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | MEN1 581/4885KMT2A 1639/4885TDP1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.